RGD Reference Report - Lovastatin modulates glycogen synthase kinase-3beta pathway and inhibits mossy fiber sprouting after pilocarpine-induced status epilepticus. - Rat Genome Database

Send us a Message



Submit Data |  Help |  Video Tutorials |  News |  Publications |  Download |  REST API |  Citing RGD |  Contact   

Lovastatin modulates glycogen synthase kinase-3beta pathway and inhibits mossy fiber sprouting after pilocarpine-induced status epilepticus.

Authors: Lee, CY  Jaw, T  Tseng, HC  Chen, IC  Liou, HH 
Citation: Lee CY, etal., PLoS One. 2012;7(6):e38789. doi: 10.1371/journal.pone.0038789. Epub 2012 Jun 26.
RGD ID: 10045560
Pubmed: PMID:22761705   (View Abstract at PubMed)
PMCID: PMC3383707   (View Article at PubMed Central)
DOI: DOI:10.1371/journal.pone.0038789   (Journal Full-text)

This study was undertaken to assay the effect of lovastatin on the glycogen synthase kinase-3 beta (GSK-3beta) and collapsin responsive mediator protein-2 (CRMP-2) signaling pathway and mossy fiber sprouting (MFS) in epileptic rats. MFS in the dentate gyrus (DG) is an important feature of temporal lobe epilepsy (TLE) and is highly related to the severity and the frequency of spontaneous recurrent seizures. However, the molecular mechanism of MFS is mostly unknown. GSK-3beta and CRMP-2 are the genes responsible for axonal growth and neuronal polarity in the hippocampus, therefore this pathway is a potential target to investigate MFS. Pilocarpine-induced status epilepticus animal model was taken as our researching material. Western blot, histological and electrophysiological techniques were used as the studying tools. The results showed that the expression level of GSK-3beta and CRMP-2 were elevated after seizure induction, and the administration of lovastatin reversed this effect and significantly reduced the extent of MFS in both DG and CA3 region in the hippocampus. The alteration of expression level of GSK-3beta and CRMP-2 after seizure induction proposes that GSK-3beta and CRMP-2 are crucial for MFS and epiletogenesis. The fact that lovastatin reversed the expression level of GSK-3beta and CRMP-2 indicated that GSK-3beta and CRMP-2 are possible to be a novel mechanism of lovatstain to suppress MFS and revealed a new therapeutic target and researching direction for studying the mechanism of MFS and epileptogenesis.

RGD Manual Disease Annotations    Click to see Annotation Detail View
TermQualifierEvidenceWithReferenceNotesSourceOriginal Reference(s)
status epilepticus treatmentISODpysl2 (Rattus norvegicus)10045560; 10045560 RGD 
status epilepticus treatmentIEP 10045560; 10045560 RGD 
status epilepticus treatmentISOGsk3b (Rattus norvegicus)10045560; 10045560 RGD 

Objects Annotated

Genes (Rattus norvegicus)
Dpysl2  (dihydropyrimidinase-like 2)
Gsk3b  (glycogen synthase kinase 3 beta)

Genes (Mus musculus)
Dpysl2  (dihydropyrimidinase-like 2)
Gsk3b  (glycogen synthase kinase 3 beta)

Genes (Homo sapiens)
DPYSL2  (dihydropyrimidinase like 2)
GSK3B  (glycogen synthase kinase 3 beta)


Additional Information